1h Free Analyst Time
The non-insulin diabetes therapeutics market is forecasted to grow by USD 39.72 billion during 2023-2028, accelerating at a CAGR of 12.17% during the forecast period. The report on the non-insulin diabetes therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing number of people with type 2 diabetes, growing prevalence of diabetes among people aged 6-19 and 35-50, and recent product approvals.
The non-insulin diabetes therapeutics market is segmented as below:
By Type
- DPP4 inhibitors
- GLP-1 receptor agonists
- SGLT2 inhibitors
- Others
By Distribution Channel
- Offline
- Online
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the non-insulin diabetes therapeutics market covers the following areas:
- Non-insulin diabetes therapeutics market sizing
- Non-insulin diabetes therapeutics market forecast
- Non-insulin diabetes therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global non-insulin diabetes therapeutics market: Abbott Laboratories, AstraZeneca Plc, Better Therapeutics Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and The Cleveland Clinic Foundation.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is innovations in therapies."
According to the report, one of the major drivers for this market is the increasing number of people with type 2 diabetes.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AstraZeneca PLC
- Better Therapeutics Inc.
- Boehringer Ingelheim International GmbH
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck KGaA
- Novartis AG
- Novo Nordisk AS
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- The Cleveland Clinic Foundation
